MedTrace Logo

Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction

NCT04944706 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2025-01-09

No results posted yet for this study

Summary

Main objective: To evaluate the efficacy, safety and clinical dose exploration of Qishen Yiqi dripping pills in the treatment of chronic heart failure with preserved ejection fraction.

Conditions

  • Chronic Heart Failure With Preserved Ejection Fraction

Interventions

DRUG

Qishen Yiqi dripping pills 2 bags/time + Qishen Yiqi dripping pills placebo 2 bags/time

Take 3 times a day after meals,24 weeks

DRUG

Qishen Yiqi dripping pills 4 bags/time

Take 3 times a day after meals,24 weeks

DRUG

Qishen Yiqi dripping pills placebo 4 bags/time

Take 3 times a day after meals,24 weeks

Sponsors & Collaborators

  • Tasly Pharmaceutical Group Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-27
Primary Completion
2024-12-19
Completion
2024-12-19

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04944706 on ClinicalTrials.gov